SLC7A2 and non-small cell lung carcinoma: Because there were nearly 200 DEGs related to immune responses in cisplatin- and paclitaxel- resistant NSCLC cells, and tumor infiltrating lymphocytes are crucial for tumor patients’ survival, we tested if SLC7A2 expression could be associated with immune infiltration in NSCLC in the TIMER database.